|Other Names||Integral membrane protein 2B, Immature BRI2, imBRI2, Protein E25B, Transmembrane protein BRI, Bri, BRI2, membrane form, Mature BRI2, mBRI2, BRI2 intracellular domain, BRI2 ICD, BRI2C, soluble form, Bri23 peptide, Bri2-23, ABri23, C-terminal peptide, P23 peptide, ITM2B, BRI, BRI2|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13163b was selected from the C-term region of ITM2B. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Plays a regulatory role in the processing of the beta- amyloid A4 precursor protein (APP) and acts as an inhibitor of the beta-amyloid peptide aggregation and fibrils deposition. Plays a role in the induction of neurite outgrowth. Functions as a protease inhibitor by blocking access of secretases to APP cleavage sites. Bri23 peptide prevents aggregation of APP beta-amyloid protein 42 peptide into toxic oligomers.|
|Cellular Location||Integral membrane protein 2B: Golgi apparatus membrane; Single-pass type II membrane protein. Note=Immature BRI2 (imBRI2) is cleaved by furin in the Golgi into mBRI2 and a Bri23 peptide mBRI2 is transported to the plasma membrane and Bri23 peptide is secreted Bri23 peptide: Secreted. Note=Detected in the cerebral spinal fluid (CSF).|
|Tissue Location||Ubiquitous. Expressed in brain.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Amyloid precursor proteins are processed by beta-secretaseand gamma-secretase to produce beta-amyloid peptides which form thecharacteristic plaques of Alzheimer disease. This gene encodes atransmembrane protein which is processed at the C-terminus by furinor furin-like proteases to produce a small secreted peptide whichinhibits the deposition of beta-amyloid. Mutations which result inextension of the C-terminal end of the encoded protein, therebyincreasing the size of the secreted peptide, are associated withtwo neurogenerative diseases, familial British dementia andfamilial Danish dementia.
Peng, S., et al. Biochem. Biophys. Res. Commun. 393(3):356-361(2010)Matsuda, S., et al. J. Biol. Chem. 284(23):15815-15825(2009)Matsuda, S., et al. Mol Neurodegener 4, 41 (2009) :Tsachaki, M., et al. Biotechnol J 3(12):1548-1554(2008)Kim, J., et al. J. Neurosci. 28(23):6030-6036(2008)
If you have any additional inquiries please email technical services at email@example.com.